Gene variant reduces cholesterol by two mechanisms

High levels of low-density lipoprotein (LDL) cholesterol increases the risk for coronary heart disease.

A variant in the encoding the protein sortilin is associated with reduced plasma LDL levels and a decreased risk of heart attack.

This variant results in markedly higher sortilin in liver.

Dr. Daniel Rader and colleagues at the University of Pennsylvania in Philadelphia have uncovered a two-pronged mechanism for the change in LDL observed.

Using a mouse model system, the Rader team found that increased liver sortilin is responsible for reducing secretion of APOB, a protein that transports LDL to tissue, and also triggers LDL breakdown.

Both of these effects were dependent on a cellular process known as lysosomal targeting.

Their data provide functional evidence that genetically-increased hepatic sortilin in humans reduces LDL by increasing LDL degradation, thus removing LDL from circulation, as well as decreasing APOB.

More information: Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism, Journal of Clinical Investigation.

add to favorites email to friend print save as pdf

Related Stories

Bad cholesterol inhibits the breakdown of peripheral fat

Nov 20, 2008

The so called bad cholesterol (LDL) inhibits the breakdown of fat in cells of peripheral deposits, according to a study from the Swedish medical university Karolinska Institutet. The discovery reveals a novel function of ...

Recommended for you

A better way to track emerging cell therapies using MRIs

Sep 19, 2014

Cellular therapeutics – using intact cells to treat and cure disease – is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination ...

User comments